Pediatrix Medical Group, Inc. Stock Price, News & Analysis

Pediatrix Medical Group, Inc. (NYSE: MD) will hold an investor conference call and webcast on May 2, 2023, at 9:00 a.m. ET, to discuss operational results for the quarter ending March 31, 2023. A detailed press release will be available on the same day before the markets open. Pediatrix is recognized as a leading provider of physician services in the U.S., focusing on maternity, neonatal, and pediatric care. The organization operates through more than 5,000 affiliated clinicians across 37 states. It emphasizes high-quality care backed by significant investments in research and safety initiatives.

Pediatrix Medical Group (NYSE: MD) has elected James D. Swift, M.D., as a director effective March 8, 2023, following his recent appointment as CEO. This election fills a seat previously held by co-founder Roger J. Medel, M.D., who is recognized for his extensive contributions to the company. Pediatrix, established in 1979, is a leading provider of physician services in the U.S., focusing on maternal-fetal medicine, neonatology, and pediatric care through over 5,000 affiliated clinicians. The company emphasizes coordinated, compassionate care supported by quality improvement and safety initiatives.

Pediatrix Medical Group (NYSE: MD) is hosting the NEO: The Conference for Neonatology from February 22-24 in Las Vegas, Nevada. This premier event addresses critical issues in neonatal care, attracting over 385 healthcare professionals. The CDC recently reported a 4% increase in the U.S. premature birth rate, now at 10.49%, emphasizing the importance of specialized neonatal care. Pediatrix, serving nearly 1 million neonates annually, is dedicated to improving outcomes for high-risk infants. The conference will feature esteemed speakers and the presentation of the Legends in Neonatology Award.

Pediatrix Medical Group, Inc. (NYSE: MD) reported fourth-quarter earnings from continuing operations at $0.29 per share, down from $0.47 in the same quarter last year. Net revenue for Q4 2022 rose to $514 million, a year-over-year increase from $498.5 million. Adjusted EBITDA decreased to $66 million from $81 million in the prior year. The company faced challenges with revenue cycle management and reported a significant drop in funds received under the CARES Act, impacting revenue growth. Looking ahead, Pediatrix projects 2023 Adjusted EBITDA between $235 million to $245 million. The firm ended the year with a strong financial position despite recent challenges.

Pediatrix Medical Group (NYSE: MD) will hold an investor conference call on February 17, 2023, at 9:00 a.m. ET, to discuss operational results for the quarter ending December 31, 2022. A press release detailing these results will be issued on the same day before market opening. Pediatrix Medical Group is the leading provider of physician services in the U.S., specializing in obstetrics, maternal-fetal medicine, neonatology, and over 20 pediatric subspecialties. The company has grown significantly since its founding in 1979, now employing over 5,000 clinicians across 37 states.

Pediatrix Medical Group (NYSE: MD) has appointed James D. Swift, M.D., as the new Chief Executive Officer, succeeding Mark S. Ordan, who has transitioned to Executive Chair. This leadership change, effective at year-end, follows Ordan's tenure since July 2020, during which he oversaw significant strategic developments, including a focus on women's and children's care and a strengthening of the company's balance sheet. Dr. Swift has been with Pediatrix since 2009, previously serving as Chief Development Officer and COO.